The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Phase 2

Completed

• Conditions: Depressive Disorder, Major

• Registration Number: NCT00163059
• Lead Sponsor: Pfizer

Brief Summary

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Detailed Description

Not available

Study Timeline

• Study Start: 2004-05
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-13
• Study Completion: 2005-12
• Status Verified: 2006-09
• Last Update Submitted: 2006-09-21
• Last Update Posted: 2006-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Primary DSM-IV diagnosis of MDD

Exclusion Criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
MADRS

Secondary Outcome Measures

Name	Time	Method
HAM-D

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Wichita, Kansas, United States